{"created":"2021-03-01T06:17:21.687585+00:00","id":10528,"links":{},"metadata":{"_buckets":{"deposit":"d2bd7719-e29b-4d92-b7ef-3be8f48f43b3"},"_deposit":{"created_by":17,"id":"10528","owners":[17],"pid":{"revision_id":0,"type":"depid","value":"10528"},"status":"published"},"_oai":{"id":"oai:nagoya.repo.nii.ac.jp:00010528","sets":["499:508:509:1171"]},"author_link":["31920","31921","31922","31923","31924","31925","31926","31927"],"item_1615768549627":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_9_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2009-09","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3-4","bibliographicPageEnd":"156","bibliographicPageStart":"151","bibliographicVolumeNumber":"71","bibliographic_titles":[{"bibliographic_title":"Nagoya Journal of Medical Science","bibliographic_titleLang":"en"}]}]},"item_9_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Interleukin (IL)-8, a proinflammatory chemokine, has been reported to have angiogenic activity and to be responsible for tumor-associated angiogenesis in several cancers. The polymorphism IL-8 T-251A (rs4073) is known to be associated with the expression of IL-8 protein and is related to several cancers. A serum anti-p53 antibody, a new tumor marker, increases in accordance with the mutation of tumor suppressor\ngene p53. Previous studies have reported the association between IL-8 and p53 mutation in cancer cells or tissues. Therefore, we hypothesized that IL-8 polymorphism might be associated with serum anti-p53\nantibody levels. Study subjects were 197 participants (103 males and 94 females, aged 15 to 56 years) who were enrolled in a case-control study on peptic ulcer disease from January to March 2007 in the Uzbekistan Republic. Serum anti-p53 antibody, CEA, and CA19-9 levels were measured, and IL-8 T-251A was genotyped. The A allele frequency in control subjects was 0.48, which is close to the previous reports for Caucasian populations. The proportion of subjects with positive anti-p53 antibodies (higher than 1.3 U/mL) was greater for AA genotype carriers compared to T allele carriers (17% for AA, and 6% for TA+TT; OR 3.4, p = 0.025 after adjusting for age, sex, comorbidity and ethnicity). Such a difference was not observed for either CEA or CA19-9. We demonstrated that the IL-8 -251 AA genotype was associated with higher anti-p53 antibodies than those of the reference range. Further studies are warranted to clarify\nwhether those with this genotype carrier are susceptible to malignant diseases.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_9_identifier_60":{"attribute_name":"URI","attribute_value_mlt":[{"subitem_identifier_type":"HDL","subitem_identifier_uri":"http://hdl.handle.net/2237/12351"}]},"item_9_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.18999/nagjms.71.3-4.151","subitem_identifier_reg_type":"JaLC"}]},"item_9_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Nagoya University School of Medicine","subitem_publisher_language":"en"}]},"item_9_select_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"publisher"}]},"item_9_source_id_61":{"attribute_name":"ISSN（Online）","attribute_value_mlt":[{"subitem_source_identifier":"2186-3326","subitem_source_identifier_type":"EISSN"}]},"item_9_source_id_7":{"attribute_name":"ISSN（print）","attribute_value_mlt":[{"subitem_source_identifier":"0027-7622","subitem_source_identifier_type":"PISSN"}]},"item_9_text_14":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_text_value":"application/pdf"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"OKADA, RIEKO","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"31920","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"RAHIMOV, BAKHODIR","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"31921","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"AHN, KEUN SOO","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"31922","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"ABDIEV, SHAVKAT","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"31923","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"MALIKOV, YUSUF","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"31924","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"BAHRAMOV, SAIDKARIM","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"31925","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"NAITO, MARIKO","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"31926","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"HAMAJIMA, NOBUYUKI","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"31927","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-02-20"}],"displaytype":"detail","filename":"p151-156_Okada.pdf","filesize":[{"value":"93.0 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"p151-156_Okada.pdf","objectType":"fulltext","url":"https://nagoya.repo.nii.ac.jp/record/10528/files/p151-156_Okada.pdf"},"version_id":"4abd599a-94af-4921-b1c7-d2ef3c6908a7"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Interleukin-8","subitem_subject_scheme":"Other"},{"subitem_subject":"Anti-p53 antibody","subitem_subject_scheme":"Other"},{"subitem_subject":"Genetic polymorphism","subitem_subject_scheme":"Other"},{"subitem_subject":"Uzbekistan","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"INTERLEUKIN-8 T-251A POLYMORPHISM WAS ASSOCIATED WITH POSITIVE ANTI-p53 ANTIBODIES IN UZBEKISTAN POPULATION","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"INTERLEUKIN-8 T-251A POLYMORPHISM WAS ASSOCIATED WITH POSITIVE ANTI-p53 ANTIBODIES IN UZBEKISTAN POPULATION","subitem_title_language":"en"}]},"item_type_id":"9","owner":"17","path":["1171"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2009-11-30"},"publish_date":"2009-11-30","publish_status":"0","recid":"10528","relation_version_is_last":true,"title":["INTERLEUKIN-8 T-251A POLYMORPHISM WAS ASSOCIATED WITH POSITIVE ANTI-p53 ANTIBODIES IN UZBEKISTAN POPULATION"],"weko_creator_id":"17","weko_shared_id":-1},"updated":"2023-11-16T06:35:19.365145+00:00"}